Clinical trials: Lung Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
This is a Phase 1b/2 study. In Phase 1b, subjects will know the treatment they are receiving. Subjects will receive Erlotinib + U3-1287.
- Trial name
- NCT01211483
- Testing
- U3-1287, Erlotinib
- Where
- 52 sites in United States, Austria and 11 more
- Volunteers
- 222 people
- Sponsor
- Daiichi Sankyo
Lung Cancer, Mesothelioma
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Objectives: Objectives The primary objective of this study is to: To assess 4-month disease control rate (DCR) in pre-treated patients with unresectable malignant pleural mesothelioma (MPM) treated with alisertib The secondary…
- Trial name
- NCT02293005
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate whether the combination of neoadjuvant chemotherapy (chemotherapy before surgery) plus ipilimumab for lung cancer increases the number of patients with detectable circulating T cells with…
- Trial name
- TOP1201 IPI (NCT01820754)
- Testing
- Ipilimumab, Paclitaxel, Cisplatin, Carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Duke University
Non-small Cell Lung Cancer, Renal Cell Carcinoma
Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma
This is a pilot study of biomarker evaluation and safety of pre-incisional ketorolac for patients undergoing surgical resection for non-small cell lung cancer and renal cell carcinoma.
- Trial name
- NCT04495894
- Testing
- Preoperative Ketorolac
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Emory University
B-Cell Neoplasm, Estrogen Receptor Negative
18F-FSPG PET/CT for Cancer Patients on Therapy
The goal of this phase 2 study trial is to evaluate the utility of the radiolabel 18F-FSPG used before and after treatment to diagnose, predict, and evaluate response to therapy in patients with a wide variety of metastatic…
- Conditions
- B-Cell Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Renal Cell Cancer
- Trial name
- NCT02599194
- Testing
- 18F-FSPG, 18F-FDG
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Andrei Iagaru
Prostate Cancer
A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
This research study is being done to measure the clinical benefit associated with cabozantinib (XL184) in men who have prostate cancer that has spread to visceral organs (organs other than bone or lymph nodes) and no longer…
- Trial name
- NCT01834651
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Edwin Posadas, MD
Carcinoma, Non-Small-Cell Lung
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
Using a laboratory test (VeriStrat), patients with relapsed squamous cell lung cancer are assigned to two strata, VSG (VeriStrat Good) and VSP (VeriStrat Poor).
- Trial name
- EMPHASIS (NCT01652469)
- Testing
- Erlotinib, Docetaxel
- Where
- 32 sites in Austria, Belgium and 10 more
- Volunteers
- 81 people
- Sponsor
- ETOP IBCSG Partners Foundation
Neoplasms
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02222922
- Testing
- PF-06647020 Q3W, fluconazole, PF-06647020 Q2W
- Where
- 17 sites in United States, Spain
- Volunteers
- 138 people
- Sponsor
- Pfizer
Stage IV Small Cell Lung Cancer
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized…
- Trial name
- PINNACLE (NCT01859741)
- Testing
- OMP-59R5, Etoposide, Cisplatin or Carboplatin
- Where
- 35 sites in United States
- Volunteers
- 172 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Malignant Pleural Mesothelioma, Mesothelioma
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant pleural mesothelioma (MPM).
- Trial name
- NCT02611037
- Testing
- Cisplatin, Methotrexate, Gemcitabine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasms
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
This is a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of niraparib alone and in combination with PD-1 inhibitors in participants with locally advanced and metastatic non-small cell lung cancer…
- Trial name
- NCT03308942
- Testing
- Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
- Where
- 16 sites in United States
- Volunteers
- 53 people
- Sponsor
- Tesaro, Inc.
Lung Cancer
The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
Post market prospective, non-randomized, single-arm, multicenter study, designed to demonstrate dose response of an ablation system using a percutaneous approach in patients with primary, metastatic, or recurrent primary lung…
- Trial name
- EMPRESS (NCT02323854)
- Testing
- Ablation, Surgical Resection
- Where
- 4 sites in United States, Germany
- Volunteers
- 15 people
- Sponsor
- Medtronic - MITG
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
This study has two parts: dose escalation and dose expansion. The primary objectives are: For Dose Escalation, to assess the safety and tolerability of DS-1205c when combined with osimertinib in the study population and to…
- Trial name
- NCT03255083
- Testing
- DS-1205c, Osimertinib
- Where
- 7 sites in Taiwan
- Volunteers
- 13 people
- Sponsor
- Daiichi Sankyo
Malignancy, Metastasis
Same-session MR-only Simulation and Treatment With MRI-guided Adaptive Palliative RadioTherapy
This proposed study is unique in that patients will not undergo computed tomography (CT) simulation at any point during their treatment course and will instead have same-session magnetic resonance (MR)-only simulation and…
- Conditions
- Malignancy, Metastasis, Hemoptysis, Gastrointestinal Bleeding
- Trial name
- MAP-RT (NCT03824366)
- Testing
- Volumetric MR imaging, Radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Non-small Cell Lung Cancer, Lung Cancer
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
In this research study the investigators are looking for the highest dose of a stereotactic radiation boost that can be given safely.
- Conditions
- Non-small Cell Lung Cancer, Lung Cancer, NSCLC
- Trial name
- NCT01222572
- Testing
- Stereotactic boost, Conventional RT, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Dana-Farber Cancer Institute
Non Small Cell Lung Cancer (NSCLC)
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy.
- Trial name
- NCT01905657
- Testing
- Pembrolizumab, Docetaxel
- Volunteers
- 1,034 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Neoplasms, Lung Cancer
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
This is a phase 2, multi-center, single dose, open-label, exploratory study in suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/positron emission tomography imaging based on standard of…
- Trial name
- NCT02872701
- Testing
- OTL38 for Injection, Near infrared camera imaging system, Endoscopic or Thoracic Surgery
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 100 people
- Sponsor
- On Target Laboratories, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.